Heres how it works in your body: Stimulates insulin secretion in a glucose-dependent manner (only when blood sugar is elevated) Suppresses glucagon release , reducing liver glucose production Delays gastric emptying , keeping you feeling fuller for longer Acts on brain appetite centres , reducing hunger and food cravings Half-life of 165-184 hours , enabling once-weekly dosing Learn more about Ozempic vs Wegovy vs Rybelsus differences Mounjaro (Tirzepatide): The Dual-Action Game Changer Mounjaro represents the next generation of weight-loss therapy with its innovative dual mechanism: Activates both GLP-1 AND GIP receptors (gastric inhibitory polypeptide) Enhanced insulinotropic effects through GIPs additional metabolic benefits Amplifies weight loss through both central nervous system and peripheral pathways Superior appetite suppression compared to GLP-1-only medications Improved insulin sensitivity and glucose disposal According to research published in JAMA Internal Medicine (July 2024) and confirmed in real-world 2026 studies, this dual mechanism is what gives Mounjaro its superior efficacy profile, patients are 3.2 times more likely to achieve 15% weight loss compared to Ozempic users
However, these findings are based on single time-point comparisons in a small sample, and the analyses were not adjusted for potential confounders such as BMI, dietary intake or medication use
GLP-1 Coverage Policy Timeline Frequently Asked Questions 36% cover GLP-1 medications for weight loss unchanged from 2025, though up from 26% in 2023
Designed to tighten three key areas often affected by rapid weight loss your cheeks, jawline and forehead the serum is powered by proxylane, a patented sugar-protein molecule (developed via green chemistry), as well as powerful antioxidants, which work together to reduce collagen decline and glycation
